Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: The present study was aimed at clarifying the expression of ubiquitin carboxyl‐terminal hydrolase 22 (USP22), a novel deubiquitinating enzyme gene, in colorectal cancer (CRC) and its clinical significance. Methods: USP22 expression was detected with quantitative RT‐PCR, Western blot, and immunohistochemistry (IHC) in 43 CRCs and non‐cancerous matched tissues. Furthermore, USP22 protein expression was analyzed in 192 CRC tumors by IHC to evaluate the association with survival. Results: In 43 paired fresh tissues, the expression level of USP22 was significantly higher in primary CRCs than that in the paired non‐cancerous tissues at both mRNA and protein levels (P < 0.0001). Nuclear USP22 expression significantly increased from normal mucosa through adenoma to primary carcinoma (P < 0.0001) and from primary carcinoma to liver metastasis (P = 0.021). The incidence of positive USP22 expression was 54.16% in 192 conventional CRC tissues. Notably, high USP22 expression was significantly associated with shorter disease‐specific survival (P < 0.0001) and shorter disease‐free survival (P < 0.0001). Cox regression analysis showed USP22 was an independent prognostic parameter for CRC patients. Conclusion: USP22 might be an independent predictive factor for CRC prognosis and aberrant expression of USP22 may play an essential role in colorectal carcinogenesis and liver metastasis. J. Surg. Oncol. 2011; 103:283–289. © 2010 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The complex language of chromatin regulation during transcription
Berger, S. L. (2007) · Nature · doi:10.1038/nature05915 · Cited by 2,768
Glinsky, G. V., Berezovska, O., & Glinskii, A. B. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23412 · Cited by 916 · cited 5×
“Recent experimental observations have identified a conserved BMI1-driven 11-gene signature as a key regulator of ‘‘stemness’’ in both tissue stem cells and cancer stem cells; cancer stem cells are considered essential for tumor progression and metastases of epithelial malignancies [4,5].”
BackgroundResultInfluentialHenry, K. W., Wyce, A., Lo, W.-S., Duggan, L. J., Emre, N. C. T., Kao, C.-F., Pillus, L., Shilatifard, A., Osley, M. A., & Berger, S. L. (2003) · Genes & Development · doi:10.1101/gad.1144003 · Cited by 714 · cited 1×
“The ubiquitination/deubiquitination cycle of histones H2A and H2B is important in regulating chromatin dynamics and transcription mediated, in part, via ‘‘cross-talk’’ between histone ubiquitination and methylation [24,25].”
BackgroundZhang, X.-Y., Varthi, M., Sykes, S. M., Phillips, C., Warzecha, C., Zhu, W., Wyce, A., Thorne, A. W., Berger, S. L., & McMahon, S. B. (2008) · Molecular Cell · doi:10.1016/j.molcel.2007.12.015 · Cited by 427
Zhao, Y., Lang, G., Ito, S., Bonnet, J., Metzger, E., Sawatsubashi, S., Suzuki, E., Le Guezennec, X., Stunnenberg, H. G., Krasnov, A., et al. (2008) · Molecular Cell · doi:10.1016/j.molcel.2007.12.011 · Cited by 382
Ovaa, H., Kessler, B. M., Rolén, U., Galardy, P. J., Ploegh, H. L., & Masucci, M. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308411100 · Cited by 190
Cited by
Deubiquitylating enzymes and drug discovery: emerging opportunities
Harrigan, J. A., Jacq, X., Martin, N. M., & Jackson, S. P. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.152 · Cited by 940
USP22 regulates oncogenic signaling pathways to drive lethal cancer progression
Schrecengost, R. S., Dean, J. L., Goodwin, J. F., Schiewer, M. J., Urban, M. W., Stanek, T. J., Sussman, R. T., Hicks, J. L., Birbe, R. C., Draganova-Tacheva, R. A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1954 · Cited by 126
“For example, USP22 is required for hepatocellular carcinoma (HCC) and bladder cancer growth (55, 56) is elevated in advanced melanoma (57), and independently predicts for poor prognosis in colorectal carcinoma (12), invasive breast cancer (11), gastric cancer (58), esophageal and oral squamous cell carcinoma (15, 16),…”
Ubiquitin-specific protease 22 is a deubiquitinase of CCNB1
Lin, Z., Tan, C., Qiu, Q., Kong, S., Yang, H., Zhao, F., Liu, Z., Li, J., Kong, Q., Gao, B., et al. (2015) · Cell Discovery · doi:10.1038/celldisc.2015.28 · Cited by 90
“USP22 is highly expressed in many types of human cancers, including colon cancer [26]; however, the physiological functions of USP22 and its role in tumorigenesis, as well as the underlying molecular mechanisms resulting in both normal and abnormal cell cycle regulation, are largely unknown.”
Usp22 deficiency impairs intestinal epithelial lineage specification in vivo
Kosinsky, R. L., Wegwitz, F., Hellbach, N., Dobbelstein, M., Mansouri, A., Vogel, T., Begus-Nahrmann, Y., & Johnsen, S. A. (2015) · Oncotarget · doi:10.18632/oncotarget.5412 · Cited by 34
“In particular, a role of USP22 has been suggested in non-small cell lung cancer [15, 21, 28], gastric carcinoma [29], glioma [30], pancreatic cancer [18, 28], breast [31] and colorectal cancer [25, 32, 33].”
Background
Metadata
- Authors
- Liu, Y., Yang, Y., Xu, H., & Dong, X.
- Venue
- Journal of Surgical Oncology
- Publisher
- Wiley
- Published
- 2010-12-08
- Volume
- 103
- Issue
- 3
- Pages
- 283-289
- ISSN
- 0022-4790 (ISSN-L)
- 1096-9098
- OpenAlex
- W2154247833
- Cited by
- 101
- References
- 6
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.